Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
A. A. Lo, A. Wallace, D. Oreper, N. Lounsbury, C. Havnar, X. Pechuan-Jorge, T. D. Wu, R. Bourgon, R. Jones, K. Krogh, G.-Y. Yang, O. A. Zill
The paper analyzes tumor evolution across cancer types to identify factors affecting neoantigen targeting in immunotherapy.
bioRxiv · Mar 15, 2021Cancer Biology